List of Colcrys drug patents
Colcrys is owned by Takeda Pharms Usa.
Colcrys contains Colchicine.
Colcrys has a total of 17 drug patents out of which 0 drug patents have expired.
Colcrys was authorised for market use on 29 July, 2009.
Colcrys is available in tablet;oral dosage forms.
Colcrys can be used as method of treating gout flares, for the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever, method of administering colchicine to familial mediterranean fever patients, method of using colchicine for the prophylaxis of gout flares, a method for treatment of gout flares during prophylaxis.
The generics of Colcrys are possible to be released after 17 February, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8093296 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(5 years from now) | |
| US7964648 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(5 years from now) | |
| US7981938 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(5 years from now) | |
| US7964647 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(5 years from now) | |
| US8093297 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(5 years from now) | |
| US8097655 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(5 years from now) | |
| US8415396 | TAKEDA PHARMS USA | Colchine compositions and methods |
Oct, 2028
(5 years from now) | |
| US8415395 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(5 years from now) | |
| US8093298 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(5 years from now) | |
| US7619004 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(5 years from now) | |
| US7935731 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(5 years from now) | |
| US7601758 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares |
Feb, 2029
(6 years from now) | |
| US7906519 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(6 years from now) | |
| US8440722 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(6 years from now) | |
| US8440721 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(6 years from now) | |
| US7915269 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(6 years from now) | |
| US7820681 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(6 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 29 July, 2009
Treatment: Method of treating gout flares; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; A method for treatment of gout flares during prophylaxis; Method of using colchicine for the prophylaxis of gout flares; Method of administering colchicine to familial mediterranean fever patients
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic